TRACON Pharmaceuticals, Inc. (TCON): Price and Financial Metrics
GET POWR RATINGS... FREE!
TCON POWR Grades
- Sentiment is the dimension where TCON ranks best; there it ranks ahead of 63.29% of US stocks.
- The strongest trend for TCON is in Growth, which has been heading down over the past 173 days.
- TCON's current lowest rank is in the Momentum metric (where it is better than 4.62% of US stocks).
TCON Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for TCON is 0.03 -- better than merely 8.48% of US stocks.
- With a price/sales ratio of 155.91, Tracon Pharmaceuticals Inc has a higher such ratio than 98.2% of stocks in our set.
- With a year-over-year growth in debt of -66.15%, Tracon Pharmaceuticals Inc's debt growth rate surpasses only 4.51% of about US stocks.
- If you're looking for stocks that are quantitatively similar to Tracon Pharmaceuticals Inc, a group of peers worth examining would be SEAC, RIGL, MDRX, ALLT, and ARAY.
- Visit TCON's SEC page to see the company's official filings. To visit the company's web site, go to www.traconpharma.com.
TCON Valuation Summary
- TCON's EV/EBIT ratio is -2.3; this is 107.85% lower than that of the median Healthcare stock.
- Over the past 80 months, TCON's price/earnings ratio has gone up 12.5.
- Over the past 80 months, TCON's price/earnings ratio has gone up 12.5.
Below are key valuation metrics over time for TCON.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| TCON | 2021-08-31 | 210.1 | 6.1 | -3.3 | -2.3 |
| TCON | 2021-08-30 | 209.5 | 6.1 | -3.3 | -2.3 |
| TCON | 2021-08-27 | 213.9 | 6.2 | -3.3 | -2.3 |
| TCON | 2021-08-26 | 213.3 | 6.2 | -3.3 | -2.3 |
| TCON | 2021-08-25 | 224.6 | 6.5 | -3.5 | -2.5 |
| TCON | 2021-08-24 | 221.4 | 6.4 | -3.4 | -2.5 |
TCON Growth Metrics
- Its 5 year net cashflow from operations growth rate is now at -4.09%.
- Its 4 year price growth rate is now at -96.38%.
- Its 3 year price growth rate is now at -89.01%.
The table below shows TCON's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 0.346 | -22.571 | -28.667 |
| 2021-09-30 | 0.346 | -21.083 | -25.266 |
| 2021-06-30 | 0.346 | -16.928 | -22.306 |
| 2021-03-31 | 0 | -16.609 | -17.818 |
| 2020-12-31 | 0 | -17.042 | -16.775 |
| 2020-09-30 | 0 | -17.659 | -16.4 |
TCON's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- TCON has a Quality Grade of C, ranking ahead of 39.83% of graded US stocks.
- TCON's asset turnover comes in at 0.011 -- ranking 386th of 681 Pharmaceutical Products stocks.
- ATXS, PTCT, and ZIOP are the stocks whose asset turnover ratios are most correlated with TCON.
The table below shows TCON's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.011 | 1 | 5.011 |
| 2021-03-31 | 0.000 | NA | 6.881 |
| 2020-12-31 | 0.000 | NA | 5.950 |
| 2020-09-30 | 0.000 | NA | 4.354 |
| 2020-06-30 | 0.000 | NA | 4.418 |
| 2020-03-31 | 0.000 | NA | 4.304 |
TCON Price Target
For more insight on analysts targets of TCON, see our TCON price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $14.75 | Average Broker Recommendation | 1.43 (Moderate Buy) |
TCON Stock Price Chart Interactive Chart >
TCON Price/Volume Stats
| Current price | $1.67 | 52-week high | $7.42 |
| Prev. close | $1.64 | 52-week low | $1.61 |
| Day low | $1.61 | Volume | 83,000 |
| Day high | $1.71 | Avg. volume | 115,355 |
| 50-day MA | $2.40 | Dividend yield | N/A |
| 200-day MA | $2.97 | Market Cap | 33.18M |
TRACON Pharmaceuticals, Inc. (TCON) Company Bio
Tracon Pharmaceuticals develops targeted therapies for cancer, wet age-related macular degeneration and fibrotic diseases. The company was founded in 2004 and is based in San Diego, California.
Latest TCON News From Around the Web
Below are the latest news stories about Tracon Pharmaceuticals Inc that investors may wish to consider to help them evaluate TCON as an investment opportunity.
Analysts Offer Insights on Healthcare Companies: Seagen (SGEN) and TRACON Pharmaceuticals (TCON)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Seagen (SGEN – Research Report) and TRACON Pharmaceuticals (TCON – Research Report) with bullish sentiments. Seagen (SGEN) H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Seagen today and set a price target of $200.00. The company's shares closed last Thursday at $134.85. According to TipRanks. |
TRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer InstituteSAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics today announced that the National Cancer Institute (NCI) has initiated a randomized Phase 2 trial of TRC102 in combination with chemoradiation in patients with stage III non-squamous non-small cell lung cancer (NCT05198830: https://clinicaltrials.gov/ct2/show/NCT05198830?term=TRC102&dr |
TRACON Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual ConferenceSAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate |
3 Top Penny Stocks for 2022Penny stocks are defined as stocks that trade at less than $5 a share. While penny stocks continue to be a risky bet, they are still popular among investors. These stocks may be volatile, but with due diligence, some hidden treasures may be found. Such penny stocks trading at low share prices can translate to huge gains for retail investors in terms of percentage returns. Using the TipRanks penny stock screener, let us find some of the top penny stocks. Bolt Biotherapeutics (NASDAQ: BOLT) The first one on this list is Bolt Biotherapeutics, a clinical-stage biotechnology company founded in 2015 by Dr. Edgar G. Engleman of Stanford University. |
Analysts’ Top Healthcare Picks: BridgeBio Pharma (BBIO), TRACON Pharmaceuticals (TCON)There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BridgeBio Pharma (BBIO – Research Report) and TRACON Pharmaceuticals (TCON – Research Report) with bullish sentiments. BridgeBio Pharma (BBIO) In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on BridgeBio Pharma, with a price target of $32.00. The company's shares closed last Monday at $11.38. According to TipRanks. |
TCON Price Returns
| 1-mo | N/A |
| 3-mo | -35.77% |
| 6-mo | -47.32% |
| 1-year | -72.89% |
| 3-year | -78.99% |
| 5-year | -94.91% |
| YTD | -39.71% |
| 2021 | -76.32% |
| 2020 | 400.00% |
| 2019 | -62.86% |
| 2018 | -81.19% |
| 2017 | -31.63% |
Loading social stream, please wait...